Abologix
Plan-les-ouates
About Abologix
ABOLOGIX is developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein. The treatment is designed for patients that do not respond to traditional cancer therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $177.6K
- Last round: Debt Financing (May 2021)
- Website: abologix.com
- Phone: + 41 (022) 8801010
Industries & Categories
Biotechnology, Health Care, Medical, Oncology, Therapeutics
Canonical: https://fsome.com/organization/abologix-188998 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.